National ICE-T (Immune Cell Effector Therapy) Conference -- Charlotte, NC
Saturday, April 18, 2026
8:15 AM - 3:45 PM
Chairs:
Barry Paul & Shebil Atrash
ICE-T Directors:
Nausheen Ahmed, Al Ola Abdallah, Zahra Mahmoudjafari
Session I:
CAR-T and Cellular Therapy Innovations
This opening scientific session delivers a comprehensive update on the rapidly evolving CAR-T landscape across hematologic malignancies and solid tumors. Experts review real-world outcomes and safety data in multiple myeloma, lymphoma, and leukemia, while also highlighting early clinical experiences and emerging targets in solid tumors. The session concludes with interactive Q&A to address practical implementation challenges.
Keynote Lecture:
The Future of Cellular and Bispecific Therapies
The keynote address offers a forward-looking perspective on innovation in cellular therapy and bispecific antibodies, including emerging platforms, pipeline developments, and anticipated shifts in clinical practice.
Session II:
Bispecific Antibodies and T-Cell Engagers
Session II explores the expanding role of bispecific antibodies in multiple myeloma, lymphoma, and leukemia. Faculty discuss efficacy data, patient selection, sequencing strategies, and management of immune-related toxicities. A dedicated case-based panel provides practical guidance on CRS, neurotoxicity, and infection prophylaxis in patients receiving T-cell engagers.
Symposium & Student Presentations
Attendees enjoy a working lunch featuring industry-supported or case-based discussions alongside USMIRC student research presentations, highlighting the next generation of immunotherapy investigators.
Debate!
CAR-T vs Bispecific Antibodies in First Relapse Multiple Myeloma
A dynamic, expert-led debate examines the optimal treatment strategy for first relapse multiple myeloma. Leaders in the field present evidence, clinical experience, and future considerations for CAR-T therapy versus bispecific antibody combinations.
